Nama Insights

SL Science Holding Limited (SLBT)

Healthcare · Biotechnology · NASDAQ

SL Science Holding Limited (SLBT) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.03B and a free-cash-flow yield of 0.0%. Over the most recent reported fiscal year, revenue grew 282.7%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the trailing band of its market.
AI scorecard
Hold · 4.5/10
The sections balance, or too few of them graded to call it either way. As of Oct 2, 2026.
Momentum
Trailing · -68.0% over 12 months ex. last
Bottom 20% of its market on the past year's move, per unit of the stock's own swings.
Shariah screen
Can't Tell
A figure the screen needs is missing — most often Yahoo carries no interest-income row for the company — so no ratio failed and none could be confirmed.
Off its high
-89.2%
How far the last close sits under the highest price of the past five years.
Market cap$1.03B
Trailing P/E—
Price / book—
Price / sales183.0
FCF yield0.0%
Dividend yield—
Gross margin38.4%
Operating margin-142.6%
Net margin-72.5%
Revenue growth (YoY)+282.7%
Revenue growth (3-yr annual)—
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta—
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals Incorporated $128.44B 26.6
REGN Regeneron Pharmaceuticals, Inc. $75.65B 15.6
MRNA Moderna Inc $75.43B —
ARGX argenx SE $58.21B 35.9
RVMD Revolution Medicines, Inc. $44.13B —
ONC BeOne Medicines AG $40.58B 63.2
RPRX Royalty Pharma plc $33.30B 11.0
ALNY Alnylam Pharmaceuticals, Inc. $30.93B 29.0
Explore live SLBT data on Nama Insights →

SLBT FAQ

Is SLBT a buy?
Nama's AI scorecard currently rates SL Science Holding Limited Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
Is SLBT Shariah compliant?
Nama's AAOIFI-style screen reads SL Science Holding Limited as Can't Tell. A figure the screen needs is missing — most often Yahoo carries no interest-income row for the company — so no ratio failed and none could be confirmed.